The first human trial of the nasal vaccine is currently underway.
The first human trial of the nasal vaccine is currently underway. It's been a long wait (20 years), but eventually there is some hope for people with Alzheimer's disease.
The first experimental intra-nasal vaccine for the disease is currently being administered to humans in Boston, Massachusetts and Brigham and Women's Hospital (BWH). The only medications available so far have been helpful in controlling Alzheimer's symptoms such as memory loss or insomnia.
The vaccine, which will be given by nasal spray, uses an immune modulator, a protein made from bacteria and proteins, to stimulate the immune system. Through this, scientists hope that the white blood cells in the lymph nodes will be activated which will be transferred to the brain and will lead to the removal of beta amyloid plaque - beta amyloid (beta). amyloid plaque) The accumulation of protein fragments that come together - which cause disease. It can completely slow down or stop the disease.
The purpose of the Phase 1 trial is to determine the safety and tolerability of the vaccine and to measure its effect on participants' immune response. The trial involved only 16 people between the ages of 60 and 85 with Alzheimer's symptoms.
In June this year, the Food and Drug Administration (FDA) approved the first new drug for Alzheimer's in almost 20 years, an antibody infusion called Aduhelm. This soon became controversial, however, when an FDA advisory committee questioned its usefulness and said that the evidence to improve its memory was conclusive.
In a statement, Dr. Howard Weiner, co-director of the Ann Romney Center for Neurological Diseases at BWH, called the study a "significant milestone."
He added: "If clinical trials in humans show that the vaccine is safe and effective, it could be an effective treatment for people with Alzheimer's, and Alzheimer's in people at risk. (Alzheimer's) can be given early to help prevent. "
According to the World Health Organization, about 55 million people are affected by the disease. "As the proportion of elderly people in the population continues to grow in almost every country, this number is expected to reach 78 million in 2030 and 139 million in 2050.
The first experimental intra-nasal vaccine for the disease is currently being administered to humans in Boston, Massachusetts and Brigham and Women's Hospital (BWH). The only medications available so far have been helpful in controlling Alzheimer's symptoms such as memory loss or insomnia.
The vaccine, which will be given by nasal spray, uses an immune modulator, a protein made from bacteria and proteins, to stimulate the immune system. Through this, scientists hope that the white blood cells in the lymph nodes will be activated which will be transferred to the brain and will lead to the removal of beta amyloid plaque - beta amyloid (beta). amyloid plaque) The accumulation of protein fragments that come together - which cause disease. It can completely slow down or stop the disease.
The purpose of the Phase 1 trial is to determine the safety and tolerability of the vaccine and to measure its effect on participants' immune response. The trial involved only 16 people between the ages of 60 and 85 with Alzheimer's symptoms.
In June this year, the Food and Drug Administration (FDA) approved the first new drug for Alzheimer's in almost 20 years, an antibody infusion called Aduhelm. This soon became controversial, however, when an FDA advisory committee questioned its usefulness and said that the evidence to improve its memory was conclusive.
In a statement, Dr. Howard Weiner, co-director of the Ann Romney Center for Neurological Diseases at BWH, called the study a "significant milestone."
He added: "If clinical trials in humans show that the vaccine is safe and effective, it could be an effective treatment for people with Alzheimer's, and Alzheimer's in people at risk. (Alzheimer's) can be given early to help prevent. "
According to the World Health Organization, about 55 million people are affected by the disease. "As the proportion of elderly people in the population continues to grow in almost every country, this number is expected to reach 78 million in 2030 and 139 million in 2050.
.jpg)
0 Comments